Min Jun

Scientia Associate Professor and Program Lead, The George Institute for Global Health, Faculty of Medicine, UNSW Sydney; kidney epidemiology

[NHMRC @nhmrc]

Dr Sradha Kotwal of @UNSW and @georgeinstitute has developed the Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE), aiming to identify an effective drug to prevent CKD progression #KidneyHealthForAll #WorldKidneyDay

[Brendon Neuen @brendonneuen]

Come work with us!

We have an exciting opening for a biostatistician to join the @georgeinstitute's Renal & Metabolic Division

Great opportunity to work on large-scale cardiorenal randomised trials and routinely collected data

https://t.co/PNSKoJvT2L

DM me for details

[The George Institute for Global Health @georgeinstitute]

"I wanted to look into an area of research that had the biggest impact on society."

Hear more from Nelson about his work on cardiovascular prevention and his long-term goals for his future work via @heartfoundation: https://t.co/R9wRH3vxU9

[AJKD @AJKDonline]

Kidney Function, Albuminuria and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

https://t.co/s6g9BN3LuL

@_jeffreyha @DearbhlaKelly4 @brendonneuen @VladoPerkovic @MinJun____ @badves @georgeinstitute @UNSWMedicine #VisualAbstract

[KIReports @KIReports]

The Prevalence of #ChronicKidneyDisease in Australian #PrimaryCare: Analysis of a National General Practice Dataset

#VisualAbstract by @jmteakell

https://t.co/F3YfR4nGz9

@MinJun____ @brendonneuen @SradhaKotwal @Badves @davidpeiris @jardine_meg @VladoPerkovic @georgeinstitute

[Brendon Neuen @brendonneuen]

Improved uptake of SGLT2i in people with CKD has the potential to substantially reduce the incidence of kidney failure in Australia

Implementation now critical to realising these population level benefits

Our new paper #openaccess in @LancetRH_WPac

https://t.co/PsOzzMJXyi

[Brendon Neuen @brendonneuen]

Latest granular data on CKD trends in Australia

CKD is common & increasing year on year

UACR testing remains abysmally low

Major opportunities for early detection & treatment to prevent cardiovascular & kidney disease

Led by @MinJun____ in @KIReports: https://t.co/hmW4k8tlYm

[Min Jun @MinJun____]

@rohinajoshi @UNSWAGSM @UNSW Congratulations Rohina!

[Amit Garg @AmitXGarg]

#ICYMI, check out this #ICESKDT study by @_jeffreyha and team that focused on determining the benefit–risk profile of rivaroxaban versus warfarin for atrial fibrillation in patients with #CKD. https://t.co/Jpmc9qGMMR @ICESOntario @MinJun____ 1/

[The George Institute for Global Health @georgeinstitute]

Congratulations to @SradhaKotwal for securing @nhmrc funding to test new treatments in people with #ChronicKidneyDisease at trial centres in Australia & other countries.

🔗https://t.co/V1ccX02XVL

[Brendon Neuen @brendonneuen]

The largest & most comprehensive analysis of the association between SGLT2i, blood pressure variability & cardiorenal outcomes

While SGLT2i reduce BP, they have little to no effect on BP variability

New #openaccess in @JAHA_AHA led by @Fletcher_RA

https://t.co/4ausKnVKi3

[Jeffrey Ha @jeffreyha.bsky.social @_jeffreyha]

Sharing this real-world study 🇦🇺🇨🇦showing favorable⚖️ safety🩸& effectiveness of Riva vs Warfarin across broad range of kidney fn with some imp safety data in those with greatly ⏬ kidney fn @MinJun____ @georgeinstitute @UNSWMedicine https://t.co/hcy7O0QTIV

[SevenOaksCDIC @SevenOaksCDIC]

Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia 🇦🇺 and Canada 🇨🇦. @KidneyMed

➡️ https://t.co/hem8M8ONIN

[The TRACK Trial @TRACK_trial]

Congratulations to Drs Majed Al Jeraisy, Mohammed Tawhari and @Ahmed_Shaman from @kaimrc_ksa for enrolling their FIRST three patients in TRACK. We welcome Saudi Arabia 🇸🇦 to the TRACK trial.

[The George Institute for Global Health @georgeinstitute]

Do multifaceted interventions or care bundles reduce #Dialysis catheter related bloodstream infections?
Our researchers @SradhaKotwal and team have published ✍️imp new findings from their @reducction trial today in the @bmj_latest:
▶️https://t.co/RVN1JuUAAG

[Martin Gallagher @kidneybloke]

@reducction @SradhaKotwal @dialysisbloke @sarah_scoggan @NephMcDonald @georgeinstitute Also provides impt insights into the scale of Hawthorne effect in such evidence implementation studies

[Min Jun @MinJun____]

Our studies found that as many as 434 million people across Asia could have chronic kidney disease and that it affects women and men differently. Urgent action in Asia is needed to prevent and manage CKD, including equitable policies that address the needs of both women and men

[The George Institute for Global Health @georgeinstitute]

Millions of people with #ChronicKidneyDisease die annually because they cannot afford treatment. New research builds a clearer picture of the growing rates of #KidneyDisease in Asia & how it affects women & men differently. #WorldKidneyDay2022

🔗Read more https://t.co/uspECvxWWQ

[Min Jun @MinJun____]

@alta_schutte Oh no, sorry to hear Alta - hope you feel better soon. Take care

[Brendon Neuen @brendonneuen]

Fantastic opportunity to work on practice changing trials and big data with collaborative colleagues, and to make a global impact - join us!! @GLDiTanna @MinJun____ @ArnottClare @SradhaKotwal @Badves @alta_schutte

[Min Jun @MinJun____]

@georgeinstitute @Badves @LaurentJBillot @Dr_WuJ @UNSWMedicine @BruceNeal1 @RobynNorton8 @UNSW @GLDiTanna @vjha126 @kidneybloke @VladoPerkovic @SimonePettigrew @ACTA_org Congratulations all, fantastic news and very well deserved!